Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA OTC Head Ganley Talks Third Class, Plan B And Drug Switches

This article was originally published in The Tan Sheet

Executive Summary

This spring, FDA's Division of OTC Drug Products will be elevated to full office status within the Center for Drug Evaluation & Research. OTC Division Director Charles Ganley, MD, sat down with "The Tan Sheet" on Dec. 17 to discuss the ramifications of the organizational change, as well as hot-button issues such as the current Rx-to-OTC switch environment, possible monograph system improvements and advisory committee reviews.

You may also be interested in...



Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins

The FDA Office of Nonprescription Products' capacity to be part of a larger unit was a factor in reorganizing ONP into an office that also includes medical imaging oversight, drug center executive John Jenkins says

Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins

The FDA Office of Nonprescription Products' capacity to be part of a larger unit was a factor in reorganizing ONP into an office that also includes medical imaging oversight, drug center executive John Jenkins says

Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins

The FDA Office of Nonprescription Products' capacity to be part of a larger unit was a factor in reorganizing ONP into an office that also includes medical imaging oversight, drug center executive John Jenkins says

Related Content

Topics

UsernamePublicRestriction

Register

PS097663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel